ETFChannel.com
RARE Description — Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co.'s product categories are: biologics, which include Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and Mepsevii® (vestronidase alfa) for the treatment of Mucopolysaccharidosis VII; small molecules, which includes UX007 for the treatment of long-chain fatty acid oxidation disorders; and gene therapy, which includes DTX301 for the treatment of patients with ornithine transcarbamylase deficiency and DTX401 for the treatment of patients with glycogen storage disease type Ia.

Company Name: 
Ultragenyx Pharmaceutical Inc
Website: 
www.ultragenyx.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding RARE: 
28
Total Market Value Held by ETFs: 
$349,630,602
Total Market Capitalization: 
$2,566,000,000
% of Market Cap. Held by ETFs: 
13.63%
 ETF   RARE Weight   RARE Amount 
 VTI   0.01%   $65,621,210         
 VB   0.08%   $57,373,016         
 IWM   0.17%   $55,745,253         
 FBT   2.80%   $40,893,479         
 VBK   0.17%   $34,306,532         
 VXF   0.06%   $33,847,691         
 IBB   0.34%   $22,854,943         
 IWO   0.30%   $20,985,176         
 VHT   0.06%   $6,307,432         
 VTWO   0.16%   $2,677,280         
List of all 28 ETFs holding RARE »
Quotes delayed 20 minutes

Strong Buy (3.81 out of 4)
77th percentile
(ranked higher than approx. 77% of all stocks covered)

Analysts Forecast:
RARE Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding RARE | Ultragenyx Pharmaceutical Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2020, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.